Goldman Sachs Expects Oil Prices to Ease as Supply Surplus Returns in Late 2026
Bitget2026/10/16 13:25- Goldman Sachs forecasts moderating oil prices as global supply exceeds demand in the fourth quarter of 2026 and in 2027.
- Dated Brent crude for delivery next month trades above $130 a barrel, while benchmark Brent futures have recently exceeded $100.
- Spot Brent prices include a nearly $25 risk premium reflecting potential supply disruptions from further Middle East escalation.
- Near-record-low global inventories support restocking demand, while portfolio hedging demand also helps keep oil prices elevated.
- Higher non-Gulf production and weaker global demand have brought the oil market nearly into balance despite remaining Persian Gulf production shortfalls.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
